The Oncoflavour Study | NCT03525236 | Trialant

The Oncoflavour Study | NCT03525236 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Taste of 5 flavors	Experimental	Each patient will taste 5 products, in sequential-monadic test, randomized, one by one. Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients) For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product. Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes	Other: Tasting of flavours

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Tasting of flavours	Other	Each patient will taste 5 products, in sequential-monadic test, randomized, one by one. Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients) For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product. Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Liking of 5 different oral nutritional supplements with adapted flavors	To evaluate patient liking and perception about 5 new flavors on a 10-point scale via a sip test	20 minutes

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
33629188	Derived	de Haan JJ, Renken RJ, Moshage Y, Kluifhooft DA, Corbier C, Daly LE, Blanchard H, Reyners AKL. Self-reported taste and smell alterations and the liking of oral nutritional supplements with sensory-adapted flavors in cancer patients receiving systemic antitumor treatment. Support Care Cancer. 2021 Oct;29(10):5691-5699. doi: 10.1007/s00520-021-06049-4. Epub 2021 Feb 25.